Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today announced positive data from its Phase 2 study evaluating EDP1815 versus […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational Synthetic Biotic™ medicines for the treatment of phenylketonuria (PKU). SYNB1618 […]
The University of Texas MD Anderson Cancer Center and SNIPR BIOME announced a strategic collaboration to advance new CRISPR-based microbiome therapeutics to reduce immune-related adverse events (irAE) in patients being treated with combined immune checkpoint inhibitors. […]
Hundreds of companies globally, funded by over USD $5.9 billion in venture capital to date, are now focused on leveraging the close relationship between humans and their resident microbes. And with new scientific publications on […]
Common medications can accumulate in gut bacteria, a new study has found, altering bacterial function and potentially reducing the effectiveness of the drug. These interactions – seen for a variety of medications, such as depression, […]
EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The […]
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into a licensing agreement with The Walter Reed Army Institute of Research (WRAIR) […]
Research from APC Microbiome Ireland (APC) at University College Cork (UCC) published in the leading international scientific journal Nature Aging introduces a novel approach to reverse aspects of aging-related deterioration in the brain and cognitive function […]
The number of published scientific papers on the microbiome has increased year after year for the past decade, and is now at an all-time high. Research is moving beyond preliminary association studies, toward more sophisticated […]
DayTwo, a leader in precision nutrition with the world’s most advanced proprietary microbiome science, today announced that the company appointed David Henderson, a former founding executive member of Oscar Health, as Chief Executive Officer. The […]
South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN. The […]